文献速递核素与放射性配体治疗肿瘤 PET/CT

高肿瘤摄取与高肿瘤/肾脏吸收剂量比的177Lu标记白蛋白结合型PSMA靶向药物

177Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio.
PubMed 文献 · J Nucl Med · 2020-08-28

本研究在LNCaP荷瘤小鼠中合成并评估了含优化亲和力修饰基团和白蛋白结合基序的PSMA靶向药物,筛选出HTK03121和HTK03123。177Lu-HTK03121与177Lu-HTK03123在肿瘤中峰值摄取极高且维持至120小时,Compared with 177Lu-PSMA-617,肿瘤吸收剂量分别高18.7倍和12.7倍,肾脏仅高6.4倍和6.3倍,肿瘤/肾脏吸收剂量比分别改善2.9倍和2.0倍。

要点

  • 177Lu-HTK03121和177Lu-HTK03123在LNCaP肿瘤中峰值摄取分别为104±20.3和70.8±23.7 %ID/g,维持至120小时。
  • Compared with 177Lu-PSMA-617,两者肿瘤吸收剂量高18.7倍和12.7倍,肾脏仅高6.4倍和6.3倍。
  • 两者肿瘤/肾脏吸收剂量比分别改善2.9倍和2.0倍,有望以更低177Lu用量提高疗效。

核心结论

  • 177Lu-HTK03121和177Lu-HTK03123具有显著增强的肿瘤摄取和肿瘤/肾脏吸收剂量比,是有望临床转化治疗转移性去势抵抗性前列腺癌的候选药物。

研究设计与样本

  • 研究合成68Ga标记的DOTA偶联赖氨酸-脲基-谷氨酸类PSMA靶向药物,在LNCaP荷瘤小鼠中进行PET/CT显像和生物分布研究以优化亲和力修饰基团和白蛋白结合剂。
  • 将优化基团组合后所得衍生物用177Lu标记,在LNCaP荷瘤小鼠中进行SPECT/CT显像和生物分布研究,并用OLINDA/EXM软件计算辐射剂量。

主要发现

  • 亲和力修饰基团优化显示,含tranexamic acid-9-anthrylalanine基团的68Ga-HTK03041在注射后1小时肿瘤摄取最高(23.1±6.11 %ID/g)。
  • 白蛋白结合剂优化显示,含N-(4-(p-chlorophenyl)butanoyl)-Gly和N-(4-(p-methoxyphenyl)butanoyl)-Gly基序的68Ga-HTK03055和68Ga-HTK03086在注射后3小时肿瘤摄取约30 %ID/g,1和3小时平均肾脏摄取均低于55 %ID/g。
  • 177Lu-HTK03121和177Lu-HTK03123在LNCaP肿瘤异种移植瘤中峰值摄取分别为104±20.3和70.8±23.7 %ID/g,且维持至注射后120小时。
  • 剂量学计算显示,Compared with 177Lu-PSMA-617,177Lu-HTK03121和177Lu-HTK03123肿瘤吸收剂量分别高18.7倍和12.7倍,肾脏吸收剂量仅高6.4倍和6.3倍,肿瘤/肾脏吸收剂量比分别改善2.9倍和2.0倍。

临床怎么用

  • 该研究为临床前小鼠数据,尚不能直接指导临床用药,但提示HTK03121和HTK03123可能以更低177Lu活度实现更高肿瘤吸收剂量并降低肾脏相对剂量。

局限性

  • 研究仅基于LNCaP荷瘤小鼠的临床前显像与生物分布数据,尚未在人体中验证安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of an albumin binder has been shown to improve tumor uptake of prostate-specific membrane antigen (PSMA)-targeting radiotherapeutic agents. The aim of this study was to develop improved radiotherapeutic agents that combine an optimized affinity-modifying group and optimized albumin binders to maximize the tumor-to-kidney absorbed dose ratio. Methods:68Ga-labeled DOTA-conjugated lysine-ureido-glutamate-based PSMA-targeting agents bearing various affinity-modifying groups or albumin binders were synthesized and evaluated by PET/CT imaging and biodistribution studies in LNCaP tumor-bearing mice. The optimized affinity-modifying group and albumin binders were combined, and the resulting derivatives were radiolabeled with 177Lu and evaluated by SPECT/CT imaging and biodistribution studies in LNCaP tumor-bearing mice. Radiation dosimetry was calculated using the OLINDA/EXM software. Results: Affinity-modifying group optimization revealed that 68Ga-HTK03041 bearing a tranexamic acid-9-anthrylalanine affinity-modifying group had the highest tumor uptake (23.1 ± 6.11 percentage injected dose [%ID]/g at 1 h after injection). Albumin binder optimization showed that 68Ga-HTK03055 and 68Ga-HTK03086 bearing the N-(4-(p-chlorophenyl)butanoyl)-Gly and N-(4-(p-methoxyphenyl)butanoyl)-Gly motifs, respectively, had relatively faster tumor accumulation (∼30 %ID/g at 3 h after injection) and lower average kidney uptake (<55 %ID/g at both 1 and 3 h after injection). Combining the tranexamic acid-9-anthrylalanine affinity-modifying group with N-(4-(p-chlorophenyl)butanoyl)-Gly and N-(4-(p-methoxyphenyl)butanoyl)-Gly albumin-binding motifs generated HTK03121 and HTK03123, respectively. 177Lu-HTK03121 and 177Lu-HTK03123 had extremely high peak uptake (104 ± 20.3 and 70.8 ± 23.7 %ID/g, respectively) in LNCaP tumor xenografts, and this peak was sustained up to 120 h after injection. Dosimetry calculation showed that compared with 177Lu-PSMA-617, 177Lu-HTK03121 and 177Lu-HTK03123 delivered 18.7- and 12.7-fold higher absorbed dose to tumor but only 6.4- and 6.3-fold higher absorbed dose to kidneys, leading to 2.9- and 2.0-fold improvement in the tumor-to-kidney absorbed dose ratios. Conclusion: With greatly enhanced tumor uptake and tumor-to-kidney absorbed dose ratio, 177Lu-HTK03121 and 177Lu-HTK03123 have the potential to improve treatment efficacy using significantly lower quantities of 177Lu and are promising candidates for clinical translation to treat metastatic castration-resistant prostate cancer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kuo HT, Lin KS, Zhang Z, et al. 177Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio. J Nucl Med. 2020. PMID: 32859704. doi:10.2967/jnumed.120.250738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。